Skip to main content
. 2021 Apr 9;23(4):e24639. doi: 10.2196/24639

Table 4.

Differences in patient characteristics among the three sites.

Characteristics VCUa (n=191) VAb (n=56) Mayo Clinic (n=102) P value
Age (years), mean (SD) 57.6 (10.6) 62.8 (10.8) 59.9 (12.6) .006
Race, n (%)


<.001

Caucasian 140 (73.3) 34 (61) 97 (95.1)

African American 44 (23.0) 17 (30) 1 (0.9)

Other 8 (4.2) 5 (9) 4 (3.9)
Men, n (%) 103 (53.9) 52 (93) 58 (56.9) <.001
Comorbidity, n (%)


.03

HCVc 22 (11.5) 7 (13) 4 (3.9)

HCV+alcohol-related 74 (38.7) 19 (34) 50 (49.0)

Alcohol-related 16 (8.4) 6 (11) 2 (2.0)

NAFLDd 40 (20.9) 18 (32) 27 (26.5)

Other 39 (20.4) 6 (11) 19 (18.6)
Prior HEe, n (%) 118 (61.8) 37 (66) 52 (51.0) .11
Lactulose use, n (%) 118 (61.8) 33 (59) 51 (50.0) .15
Rifaximin use, n (%) 72 (37.7) 32 (57) 37 (36.3) .02
Taking psychoactive medications, n (%) 51 (26.7) 8 (14) 10 (9.8) .001
Taking opioids, n (%) 50 (26.2) 9 (16) 23 (22.5) .26
MELDf score on admission, mean (SD) 19.3 (8.1) 17.4 (7.1) 18.2 (8.5) .26
Reason for admission, n (%)




Infection 80 (41.9) 24 (43) 6 (5.9) <.001

HE 71 (37.2) 21 (38) 28 (27.5) .21

Renal or metabolic disease 98 (51.3) 10 (18) 18 (17.6) <.001

Gastrointestinal bleeding 40 (20.9) 7 (13) 31 (30.4) .02

Other 87 (45.5) 23 (41) 55 (53.9) .23

aVCU: Virginia Commonwealth University

bVA: Rochester Veteran Affairs Medical Center.

cHCV: hepatitis C virus.

dNAFLD: nonalcholic fatty liver disease.

eHE: hepatic encephalopathy.

fMELD: Model for End-stage Liver Disease.